CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 150 enrolled
Drug / intervention
Tacrolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00299221
NCT00299221Phase 4Completed
CompareCT.gov

Tacrolimus In Combination, Tacrolimus Alone Compared (TICTAC Trial): A Prospective Randomized Trial Of Minimized Immunosuppression In Adult Heart Transplant Recipients

Newark Beth Israel Medical Center·interventional·Posted Mar 6, 2006·Updated May 28, 2015

In Brief

A Phase 4 clinical trial evaluating Tacrolimus and combination therapy for Immunosuppression. Completed, enrolled 150 participants across 2 sites.

Detailed Summary

This was a study to compare less intense immunosuppression with a more traditional approach. The hypothesis was that less immunosuppression will provide similar protection against rejection than typical 2-3 drug therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunosuppression
CountriesUnited States
CollaboratorsAstellas Pharma Inc

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 6, 2006
Enrollment StartApr 1, 2004
Primary CompletionJun 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 20.3 years ago

Interventions

Tacrolimusdrug

tacrolimus

combination therapydrug

MMF